Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Psoriatic Arthritis

In brief

The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.

Key facts

Study ID
NCT00534313
Run by
Bristol-Myers Squibb
People needed
191
Starts
2007-11-01
Expected to finish
2011-05-01
Last updated by the study team
2012-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.